Literature DB >> 6230903

The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.

J J Pollen, K F Witztum, W L Ashburn.   

Abstract

The radionuclide bone scan 3 months after the initiation of treatment for advanced cancer of the prostate occasionally shows apparent progression of individual lesions despite clinical improvement. To determine the incidence and clinical significance of this so-called flare phenomenon, serial bone scans were reviewed in 33 patients with carcinoma of the prostate and bony metastases, who were receiving endocrine treatment for the first time. A flare reaction was seen in two (6%) of 33 bone scans obtained 3 months after initiation of treatment. A flare reaction on bone scan is an unusual phenomenon in prostatic cancer; in general, serial scans accurately depict the activity of bony metastases in these patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6230903     DOI: 10.2214/ajr.142.4.773

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  41 in total

1.  Future directions for unsealed source radionuclide therapy for bone metastases.

Authors:  V R McCready; J M O'Sullivan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-16       Impact factor: 9.236

2.  Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy--comparison with tumor markers and bone X-ray.

Authors:  K Koizumi; G Uchiyama; H Komatsu
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

Review 3.  Bone tumor imaging, then and now: review article.

Authors:  Douglas N Mintz; Sinchun Hwang
Journal:  HSS J       Date:  2014-07-16

4.  Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.

Authors:  Connie Y Chang; F Joseph Simeone; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2017-06-30       Impact factor: 2.199

Review 5.  RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Authors:  Lawrence H Schwartz; Lesley Seymour; Saskia Litière; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Elisabeth de Vries
Journal:  Eur J Cancer       Date:  2016-05-26       Impact factor: 9.162

Review 6.  A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy.

Authors:  Amy Pawson; Zonia Ghumman; Phillip H Kuo; Hossein Jadvar; Twyla Bartel; Bobby Shayegan; Katherine Zukotynski
Journal:  Can Urol Assoc J       Date:  2020-04-01       Impact factor: 1.862

7.  Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients.

Authors:  G L Smith; A P Doherty; L M Banks; J Dutton; L W Hanham; T J Christmas; R J Epstein
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

8.  A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation.

Authors:  Rhona McMenemin; Graham Macdonald; Leslie Moffat; Donald Bissett
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

9.  [Imaging diagnostics of advanced prostate cancer].

Authors:  A Kretschmer; M Seitz; A Graser; C G Stief; D Tilki
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

Review 10.  Imaging metastatic bone disease from carcinoma of the prostate.

Authors:  C Messiou; G Cook; N M deSouza
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.